What is VVOS's health score?

Vivos Therapeutics, Inc. (VVOS) has a TradeApes health score of 36 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is VVOS's estimated fair value?

Based on our 5-year discounted cash flow model, Vivos Therapeutics, Inc.'s estimated fair value is $2.35 per share, representing a 239.4% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is VVOS undervalued or overvalued?

Our model currently rates VVOS as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for VVOS... Refresh in a moment for the full analysis.

Vivos Therapeutics, Inc. (VVOS)

Healthcare Undervalued low weak

$0.69

Updated: 2026-06-05

TradeApes Score

Financial Strength

35 Weak

Operating Trend

38 Weak

Relative Value

40 Weak

Capital Allocation

30 Weak

Risk

35 Weak

Est. Fair Value $2.35

DCF Upside +239.4%

Sector Rank #2887 of 6477

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

1 free score card remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.